XtalPi
About XtalPi
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Company Metrics
- Employees: 501-1000
- Monthly Visits: 2791
- Tech Stack: 12 active products
Financial Information
- Estimated Revenue:
- Total Funding: 786401703 USD
- Last Funding: 400000000 USD (Series D)
- Funding Status: Late Stage Venture
Technology Stack
XtalPi actively uses 12 products in their tech stack.
Market Presence
Industries: Artificial Intelligence, Biotechnology, Pharmaceutical
Headquarters: Cambridge, Massachusetts, United States
Leadership
- Sarah Trice - COO, Head of US Operations LinkedIn
Employees
- Lipeng Lai - Co-founder (LinkedIn)
- Peiyu Zhang - Chief Scientific Officer (LinkedIn)
- Yide Jiang - Chief Strategy Officer (LinkedIn)